BB-101 not checked

Blue Blood Biotech Corp.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
1 active
2 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Subjects will be randomized to receive BB-101 or placebo, and expected 32 subjects for each arm.”In the company’s words, NCT06383013 on ClinicalTrials.gov
Tested for
Diabetic Foot Ulcer
Main trialPhase 2
“This is a randomized, double-blinded, vehicle-controlled, parallel, phase II study to evaluate the efficacy and safety of topical BB-101 for the treatment of diabetic lower leg and foot ulcer.”In the company’s words, NCT06383013 on ClinicalTrials.gov

Other drugs for Diabetic Foot Ulcer

All 13 drugs for Diabetic Foot Ulcer

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 2Recruiting 31 Dec 2027 BB-101 for the Treatment of Diabetic Lower Leg and Foot Ulcers
Phase 1Completed 1 Dec 2021 BB-101 for Treatment of Diabetic Lower Leg and Foot Ulcers
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow BB-101

Following is part of Solo: you see every change to BB-101 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in